The First Non-Steroidal Potential Therapy for Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder that results in the inability to produce the critical ‘stress’ hormone cortisol. Although CAH testing is a part of the newborn screening program, there are currently only steroidal FDA-approved therapies for CAH. CAH is typically treated with chronic, high-dose steroids often resulting in significant side effects. Spruce’s lead product candidate for CAH, Tildacerfont (SPR001), is intended to correct hormone imbalance, giving patients a therapeutic option that treats their underlying disease and reduces their steroid burden.
Congenital Adrenal Hyperplasia Adult Clinical Trial
The CAHmelia 203 study is now open to screening and CAHmelia 204 will open shortly. To learn more, and see if you may qualify, go to CAHstudy.com or clinicaltrials.gov
